We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Cardinal Health (CAH) Up 4.4% Since the Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Cardinal Health, Inc. (CAH - Free Report) . Shares have added about 4.4% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Cardinal Health Inc. (CAH - Free Report) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Revenues increased 5% on a year-over-year basis to $33.1 billion. The figure however came below the Zacks Consensus Estimate of $33.4 billion.
Quarter Details
Pharmaceutical revenues increased 5% to $29.7 billion due to strong growth from existing and net new distribution customers. Strong performance by the Specialty business also drove results.
Medical segment revenues increased 8% to $3.4 billion. Higher contribution from acquisitions and net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Pharmaceutical segment profit in the quarter decreased 14% to $537 million due to generic pharmaceutical pricing and the loss of a large Pharmaceutical Distribution customer. This was partially offset by solid performance by Red Oak Sourcing.
Medical segment profit soared 50% to $159 million due to higher contribution from Cardinal Health Brand products.
Distribution, selling, general and administrative (SG&A) expenses decreased 1% on a year-over-year basis to $910 million in the reported quarter. Net income declined 11% to $633 million from last fiscal year's $709 million.
Financial Condition
Cash and cash equivalents were $1.88 billion as of Dec 31, 2016 compared with $2.36 billion as of Jun 30, 2016. Long-term debt was $4.86 billion as of Dec 31, 2016 compared with the Jun 30, 2016 level of $4.95 billion.
Guidance
Based on fiscal second-quarter results, the company lowered its fiscal 2017 guidance range for adjusted earnings per share from continuing operations to $5.35 to $5.50 from $5.40 to $5.60. The outlook represents growth of approximately 2% to 5% from the prior fiscal year.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been seven revisions lower for the current quarter.
At this time, Cardinal Health's stock has a strong Growth Score of 'A', though it is lagging a lot on the momentum front with a 'D'. However, the stock was allocated a grade of 'A' on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'A'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and growth investors.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Interestingly, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Cardinal Health (CAH) Up 4.4% Since the Last Earnings Report?
It has been about a month since the last earnings report for Cardinal Health, Inc. (CAH - Free Report) . Shares have added about 4.4% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Cardinal Health (CAH - Free Report) Q2 Earnings Beat Estimates, Rise Y/Y
Cardinal Health Inc. (CAH - Free Report) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Revenues increased 5% on a year-over-year basis to $33.1 billion. The figure however came below the Zacks Consensus Estimate of $33.4 billion.
Quarter Details
Pharmaceutical revenues increased 5% to $29.7 billion due to strong growth from existing and net new distribution customers. Strong performance by the Specialty business also drove results.
Medical segment revenues increased 8% to $3.4 billion. Higher contribution from acquisitions and net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Pharmaceutical segment profit in the quarter decreased 14% to $537 million due to generic pharmaceutical pricing and the loss of a large Pharmaceutical Distribution customer. This was partially offset by solid performance by Red Oak Sourcing.
Medical segment profit soared 50% to $159 million due to higher contribution from Cardinal Health Brand products.
Distribution, selling, general and administrative (SG&A) expenses decreased 1% on a year-over-year basis to $910 million in the reported quarter. Net income declined 11% to $633 million from last fiscal year's $709 million.
Financial Condition
Cash and cash equivalents were $1.88 billion as of Dec 31, 2016 compared with $2.36 billion as of Jun 30, 2016. Long-term debt was $4.86 billion as of Dec 31, 2016 compared with the Jun 30, 2016 level of $4.95 billion.
Guidance
Based on fiscal second-quarter results, the company lowered its fiscal 2017 guidance range for adjusted earnings per share from continuing operations to $5.35 to $5.50 from $5.40 to $5.60. The outlook represents growth of approximately 2% to 5% from the prior fiscal year.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been seven revisions lower for the current quarter.
Cardinal Health, Inc. Price and Consensus
Cardinal Health, Inc. Price and Consensus | Cardinal Health, Inc. Quote
VGM Scores
At this time, Cardinal Health's stock has a strong Growth Score of 'A', though it is lagging a lot on the momentum front with a 'D'. However, the stock was allocated a grade of 'A' on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'A'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and growth investors.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Interestingly, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.